LPAR1, Correlated With Immune Infiltrates, Is a Potential Prognostic Biomarker in Prostate Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Jul 14

PMID 32656075

Citations 56

Authors

Jingqi Shi

Dongbo Jiang

Shuya Yang

Xiyang Zhang

Jing Wang

Yang Liu

Yuanjie Sun

Yuchen Lu

Kun Yang

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is a common malignancy in men worldwide. Lysophosphatidic acid receptor 1 (LPAR1) is a critical gene and it mediates diverse biologic functions in tumor. However, the correlation between LPAR1 and prognosis in prostate cancer, as well as the potential mechanism, remains unclear. In the present study, LPAR1 expression analysis was based on The Cancer Genome Atlas (TCGA) and the Oncomine database. The correlation of LPAR1 on prognosis was also analyzed based on R studio. The association between LPAR1 and tumor-infiltrating immune cells were evaluated in the Tumor Immune Estimation Resource site, ssGSEA, and MCPcounter packages in R studio. Gene Set Enrichment Analysis and Gene Ontology analysis were used to analyze the function of LPAR1. TCGA datasets and the Oncomine database revealed that LPAR1 was significantly downregulated in prostate cancer. High LPAR1 expression was correlated with favorable overall survival. LPAR1 was involved in the activation, proliferation, differentiation, and migration of immune cells, and its expression was positively correlated with immune infiltrates, including CD4+ T cells, B cells, CD8+ T cells, neutrophils, macrophages, dendritic cells, and natural killer cells. Moreover, LPAR1 expression was positively correlated with those chemokine/chemokine receptors, indicating that LPAR1 may regulate the migration of immune cells. In summary, LPAR1 is a potential prognostic biomarker and plays an important part in immune infiltrates in prostate cancer.

Citing Articles

GPCRs: emerging targets for novel T cell immune checkpoint therapy.

Dickinson K, Yee E, Vigil I, Schulick R, Zhu Y Cancer Immunol Immunother. 2024; 73(12):253.

PMID: 39358616 PMC: 11447192. DOI: 10.1007/s00262-024-03801-7.

Downregulation of LPAR1 Promotes Invasive Behavior in Papillary Thyroid Carcinoma Cells.

Hosseini Z, Rajabi F, Morovatshoar R, Ashrafpour M, Behboodi P, Zareie D Cancer Inform. 2024; 23:11769351241277012.

PMID: 39253536 PMC: 11382228. DOI: 10.1177/11769351241277012.

The immunological landscape and silico analysis of key paraptosis regulator LPAR1 in gastric cancer patients.

Dai Y, Tang H, Jiang G, Xu Z Transl Oncol. 2024; 49:102110.

PMID: 39182362 PMC: 11388017. DOI: 10.1016/j.tranon.2024.102110.

A cuproptosis-related lncRNAs signature predicts prognosis and reveals pivotal interactions between immune cells in colon cancer.

Song J, Xie D, Wei X, Liu B, Yao F, Ye W Heliyon. 2024; 10(14):e34586.

PMID: 39114018 PMC: 11305305. DOI: 10.1016/j.heliyon.2024.e34586.

Unveiling the therapeutic promise: exploring Lysophosphatidic Acid (LPA) signaling in malignant bone tumors for novel cancer treatments.

Qi Y, Wang Y, Yuan J, Xu Y, Pan H Lipids Health Dis. 2024; 23(1):204.

PMID: 38943207 PMC: 11212261. DOI: 10.1186/s12944-024-02196-9.

References

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P . Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity. Cancer Res. 2016; 76(8):2153-65. DOI: 10.1158/0008-5472.CAN-15-1965. View

Zhang Q, Helfand B, Carneiro B, Qin W, Yang X, Lee C . Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8 T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol. 2017; 73(5):648-652. PMC: 6682506. DOI: 10.1016/j.eururo.2017.12.008. View

Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A . ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8):1091-3. PMC: 2666812. DOI: 10.1093/bioinformatics/btp101. View

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

Guerrero J, Rivera J, Quiroga T, Martinez-Perez A, Anton A, Martinez C . Novel loci involved in platelet function and platelet count identified by a genome-wide study performed in children. Haematologica. 2011; 96(9):1335-43. PMC: 3166104. DOI: 10.3324/haematol.2011.042077. View

Zhou C, Zhu C, Liu Q . Toward in silico Identification of Tumor Neoantigens in Immunotherapy. Trends Mol Med. 2019; 25(11):980-992. DOI: 10.1016/j.molmed.2019.08.001. View

Sfanos K, Yegnasubramanian S, Nelson W, De Marzo A . The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2017; 15(1):11-24. DOI: 10.1038/nrurol.2017.167. View

Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D . Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11):2498-504. PMC: 403769. DOI: 10.1101/gr.1239303. View

Becht E, Giraldo N, Lacroix L, Buttard B, Elarouci N, Petitprez F . Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218. PMC: 5073889. DOI: 10.1186/s13059-016-1070-5. View

10.

Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S . Mast cells as a potential prognostic marker in prostate cancer. Dis Markers. 2013; 35(6):711-20. PMC: 3844173. DOI: 10.1155/2013/478303. View

11.

Wang L, Knudsen E, Jin Y, Gessani S, Maghazachi A . Lysophospholipids and chemokines activate distinct signal transduction pathways in T helper 1 and T helper 2 cells. Cell Signal. 2004; 16(9):991-1000. DOI: 10.1016/j.cellsig.2004.02.001. View

12.

Erlandsson A, Carlsson J, Lundholm M, Falt A, Andersson S, Andren O . M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2018; 79(4):363-369. PMC: 6587459. DOI: 10.1002/pros.23742. View

13.

Gardner A, Ruffell B . Dendritic Cells and Cancer Immunity. Trends Immunol. 2016; 37(12):855-865. PMC: 5135568. DOI: 10.1016/j.it.2016.09.006. View

14.

Chiarugi P, Paoli P, Cirri P . Tumor microenvironment and metabolism in prostate cancer. Semin Oncol. 2014; 41(2):267-80. DOI: 10.1053/j.seminoncol.2014.03.004. View

15.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

16.

Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T . Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018; 175(7):1731-1743.e13. PMC: 6292840. DOI: 10.1016/j.cell.2018.10.014. View

17.

Plastira I, Bernhart E, Goeritzer M, DeVaney T, Reicher H, Hammer A . Lysophosphatidic acid via LPA-receptor 5/protein kinase D-dependent pathways induces a motile and pro-inflammatory microglial phenotype. J Neuroinflammation. 2017; 14(1):253. PMC: 5735906. DOI: 10.1186/s12974-017-1024-1. View

18.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U . Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018; 378(26):2465-2474. PMC: 8288034. DOI: 10.1056/NEJMoa1800536. View

19.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

20.

Harma V, Knuuttila M, Virtanen J, Mirtti T, Kohonen P, Kovanen P . Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene. 2011; 31(16):2075-89. PMC: 3330266. DOI: 10.1038/onc.2011.396. View